Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study

Bullous pemphigoid is the most common autoimmune bullous dermatosis. In recent years several studies have tried to identify the main factors of the disease related with an increased risk of death. The aim of this multicenter Italian study was to assess the risk score of death considering epidemiologic, clinical, immunological, and therapeutic factors in a cohort of patients affected by bullous pemphigoid and try to identify the cumulative survival up to 120 months.

[1]  A. Patrizi,et al.  Mortality of patients with bullous pemphigoid in Italy: a retrospective study of a monocentric experience. , 2021, Italian journal of dermatology and venereology.

[2]  D. Kivaranovic,et al.  Anti‐BP180 autoantibody levels at diagnosis correlate with 1‐year mortality rates in patients with bullous pemphigoid , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  S. Fisher,et al.  Mortality and risk factors among Israeli bullous pemphigoid patients , 2018, Archives of Dermatological Research.

[4]  H. Williams,et al.  Prospective study in bullous pemphigoid: association of high serum anti‐BP180 IgG levels with increased mortality and reduced Karnofsky score , 2018, The British journal of dermatology.

[5]  Y. Won,et al.  Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea , 2017, Annals of dermatology.

[6]  Liang Li,et al.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid , 2017, Front. Immunol..

[7]  D. Zillikens,et al.  An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone , 2017, The British journal of dermatology.

[8]  S. Fook-Chong,et al.  Multimorbidity in bullous pemphigoid: a case–control analysis of bullous pemphigoid patients with age‐ and gender‐matched controls , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  P. Jagielski,et al.  Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland , 2017, Archives of Dermatological Research.

[10]  C. Paul.  Rook's Textbook of Dermatology, 9th edn. ChristopherGriffiths, JonathanBarker, TanyaBleiker, RobertChalmers, DanielCreamer, eds. Publisher: Wiley-Blackwell, 2016; 4696 pp. ISBN: 978-1118441190. Price €654.49. , 2017 .

[11]  Enno Schmidt,et al.  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial , 2017, The Lancet.

[12]  F. Antonicelli,et al.  Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment , 2017, American Journal of Clinical Dermatology.

[13]  Michael L. Johnson,et al.  Regression coefficient-based scoring system should be used to assign weights to the risk index. , 2016, Journal of clinical epidemiology.

[14]  D. Zillikens,et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.

[15]  J. H. Lee,et al.  Mortality of patients with bullous pemphigoid in Korea. , 2014, Journal of the American Academy of Dermatology.

[16]  M. Tang,et al.  Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre , 2014, The British journal of dermatology.

[17]  S. Rojas-Farreras,et al.  Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[19]  L. Naldi,et al.  Mortality Rate in Bullous Pemphigoid: A Retrospective Monocentric Cohort Study , 2012, Dermatology.

[20]  L. Naldi,et al.  Mortality of bullous pemphigoid in Switzerland: a prospective study , 2011, The British journal of dermatology.

[21]  P. Middleton,et al.  Interventions for bullous pemphigoid. , 2010, The Cochrane database of systematic reviews.

[22]  N. Korman,et al.  Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. , 2008, Journal of the American Academy of Dermatology.

[23]  A. Ormerod,et al.  Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North‐east Scotland , 2005, The British journal of dermatology.

[24]  Michelle A. Pipitone,et al.  Immunobullous diseases. , 2005, Journal of the American Academy of Dermatology.

[25]  J. Roujeau,et al.  Prediction of survival for patients with bullous pemphigoid: a prospective study. , 2005, Archives of dermatology.

[26]  I. García-Doval,et al.  Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. , 2005, The Journal of investigative dermatology.

[27]  J. Fairley,et al.  Mortality rate of bullous pemphigoid in a US medical center. , 2004, The Journal of investigative dermatology.

[28]  M. Meurer,et al.  Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. , 2002, Archives of dermatology.

[29]  L. Vaillant,et al.  A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.

[30]  J. Roujeau,et al.  High risk of death in elderly patients with extensive bullous pemphigoid. , 1998, Archives of dermatology.

[31]  F. Wojnarowska,et al.  Lack of predictive factors for the clinical course of bullous pemphigoid. , 1992, Journal of the American Academy of Dermatology.

[32]  G. Stüttgen.  [On immunopathology of the skin]. , 1967, Der Landarzt.

[33]  R. Bergman,et al.  Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. , 2019, Acta dermato-venereologica.

[34]  Jun Li,et al.  Mortality of bullous pemphigoid in China. , 2013, JAMA dermatology.

[35]  J. Savin.  Death in bullous pemphigoid. , 1987, Clinics in dermatology.

[36]  P. Morel,et al.  [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. , 1984, Annales de dermatologie et de venereologie.